Share This Author
HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice
- S. Pascolo, N. Bervas, J. Ure, Austin G. Smith, F. Lemonnier, B. Pérarnau
- BiologyThe Journal of experimental medicine
- 16 June 1997
TLDR
Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes
- C. Jancic, A. Savina, S. Amigorena
- BiologyNature Cell Biology
- 11 March 2007
TLDR
Complete DNA sequence of yeast chromosome XI
- B. Dujon, D. Alexandraki, H. Mewes
- BiologyNature
- 2 June 1994
TLDR
Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent
- J. Probst, B. Weide, S. Pascolo
- BiologyGene Therapy
- 1 August 2007
TLDR
Immunostimulating capacities of stabilized RNA molecules
- B. Scheel, Sybilla Braedel, S. Pascolo
- Biology, ChemistryEuropean journal of immunology
- 1 February 2004
TLDR
H‐2 class I knockout, HLA‐A2.1‐transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies
- H. Firat, Francisco Garcia‐Pons, P. Langlade‐Demoyen
- BiologyEuropean journal of immunology
- 1 October 1999
TLDR
Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA
- B. Scheel, R. Teufel, S. Pascolo
- BiologyEuropean journal of immunology
- 1 May 2005
TLDR
A general strategy to enhance immunogenicity of low‐affinity HLA‐A2.1‐associated peptides: implication in the identification of cryptic tumor epitopes
- S. Tourdot, A. Scardino, K. Kosmatopoulos
- BiologyEuropean journal of immunology
- 1 December 2000
TLDR
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
- B. Weide, S. Pascolo, C. Garbe
- Medicine, BiologyJournal of immunotherapy
- 1 June 2009
TLDR
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
- B. Weide, J. Carralot, S. Pascolo
- Biology, MedicineJournal of immunotherapy
- 1 February 2008
TLDR
...
...